Agios Pharmaceuticals, Inc. AGIO
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Revenue | $54.0M | +48% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Operating income | $-472.1M | -11% | FY ending Dec 31, 2025 |
| Net income | $-412.8M | -161% | FY ending Dec 31, 2025 |
| Earnings per share | $-7.12 | -161% | FY ending Dec 31, 2025 |
| Research & development | $339.5M | +13% | FY ending Dec 31, 2025 |
| Cash from operations | $-373.0M | +4% | FY ending Dec 31, 2025 |
| Capital spending | $4.3M | +156% | FY ending Dec 31, 2025 |
| Cash | $89.1M | +17% | FY ending Dec 31, 2025 |
| Shareholders' equity | $1.2B | -23% | FY ending Dec 31, 2025 |
| Shares outstanding | 58M | +2% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 0 open-market buys ($0) and 29 sales ($5.1M) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sarah GheuensChief Medical Officer | Soldpre-set plan | 7,866 | $37.69 | $296K | Oct 26, 2026 |
| Sarah GheuensChief Medical Officer | Soldpre-set plan | 500 | $37.52 | $19K | Oct 22, 2026 |
| Sarah GheuensChief Medical Officer | Soldpre-set plan | 1,489 | $37.53 | $56K | Oct 21, 2026 |
| Sarah GheuensChief Medical Officer | Soldpre-set plan | 30,000 | $30.48 | $914K | Aug 4, 2026 |
| Sarah GheuensChief Medical Officer | Soldpre-set plan | 4,007 | $37.56 | $151K | Jul 1, 2026 |
| Brian GoffChief Executive Officer, Director | Soldpre-set plan2 fills | 19,068 | $34.71 avg | $662K | Apr 2, 2026 |
| James William BurnsChief Legal Officer | Soldpre-set plan | 3,280 | $34.71 | $114K | Apr 2, 2026 |
| Tsveta MilanovaChief Commercial Officer | Soldpre-set plan | 3,262 | $34.71 | $113K | Apr 2, 2026 |
| Cecilia JonesChief Financial Officer | Soldpre-set plan | 3,141 | $34.71 | $109K | Apr 2, 2026 |
| Krishnan ViswanadhanChief Corp Dev & Strategy | Soldpre-set plan | 2,959 | $34.71 | $103K | Apr 2, 2026 |
| Sarah GheuensChief Medical Officer | Soldpre-set plan | 2,940 | $34.71 | $102K | Apr 2, 2026 |
| Krishnan ViswanadhanChief Corp Dev & Strategy | Soldpre-set plan | 2,959 | $27.80 | $82K | Mar 5, 2026 |
| Theodore James Jr. WashburnPrincipal Accounting Officer | Sold | 5,272 | $28.88 | $152K | Mar 3, 2026 |
| Brian GoffChief Executive Officer, Director | Soldpre-set plan3 fills | 18,055 | $28.96 avg | $523K | Mar 2, 2026 |
| James William BurnsChief Legal Officer | Soldpre-set plan4 fills | 5,218 | $28.96 avg | $151K | Mar 2, 2026 |
| Cecilia JonesChief Financial Officer | Soldpre-set plan4 fills | 5,035 | $28.96 avg | $146K | Mar 2, 2026 |
| Sarah GheuensChief Medical Officer | Soldpre-set plan3 fills | 4,055 | $28.96 avg | $117K | Mar 2, 2026 |
| Tsveta MilanovaChief Commercial Officer | Soldpre-set plan2 fills | 2,868 | $28.96 avg | $83K | Mar 2, 2026 |
| Theodore James Jr. WashburnPrincipal Accounting Officer | Soldpre-set plan3 fills | 2,223 | $28.96 avg | $64K | Mar 2, 2026 |
| Tsveta MilanovaChief Commercial Officer | Soldpre-set plan | 2,872 | $27.02 | $78K | Jan 5, 2026 |
| Brian GoffChief Executive Officer, Director | Soldpre-set plan2 fills | 18,703 | $27.09 avg | $507K | Dec 30, 2025 |
| James William BurnsChief Legal Officer | Soldpre-set plan | 2,932 | $27.09 | $79K | Dec 30, 2025 |
| Sarah GheuensChief Medical Officer | Soldpre-set plan | 2,932 | $27.09 | $79K | Dec 30, 2025 |
| Tsveta MilanovaChief Commercial Officer | Soldpre-set plan | 2,932 | $27.09 | $79K | Dec 30, 2025 |
| Cecilia JonesChief Financial Officer | Soldpre-set plan | 2,932 | $27.09 | $79K | Dec 30, 2025 |
| David ScaddenDirector | Soldpre-set plan | 200 | $43.84 | $8,768 | Nov 12, 2025 |
| Sarah GheuensChief Medical Officer | Soldpre-set plan | 2,454 | $43.78 | $107K | Nov 11, 2025 |
| Sarah GheuensChief Medical Officer | Soldpre-set plan | 200 | $43.81 | $8,762 | Oct 30, 2025 |
| Sarah GheuensChief Medical Officer | Soldpre-set plan | 3,302 | $43.92 | $145K | Oct 27, 2025 |
Other insider moves (38): pay awards, option exercises, tax withholding, gifts
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sarah GheuensChief Medical Officer | Option exercisepre-set plan | 7,866 | $25.01 | $197K | Oct 26, 2026 |
| Sarah GheuensChief Medical Officer | Option exercisepre-set plan | 500 | $25.01 | $13K | Oct 22, 2026 |
| Sarah GheuensChief Medical Officer | Option exercisepre-set plan | 1,489 | $25.01 | $37K | Oct 21, 2026 |
| Jay T. BackstromDirector | Award | 1,447 | – | – | Jul 8, 2026 |
| Sarah GheuensChief Medical Officer | Option exercisepre-set plan | 8,375 | – | – | Jul 1, 2026 |
| Rahul D. BallalDirector | Option exercise | 2,816 | – | – | Jun 18, 2026 |
| Jeffrey D CapelloDirector | Option exercise | 2,816 | – | – | Jun 18, 2026 |
| Kaye I Foster-CheekDirector | Option exercise | 2,816 | – | – | Jun 18, 2026 |
| Jacqualyn A FouseDirector | Option exercise | 2,816 | – | – | Jun 18, 2026 |
| Maykin HoDirector | Option exercise | 2,816 | – | – | Jun 18, 2026 |
| Adams Catherine OwenDirector | Option exercise | 2,816 | – | – | Jun 18, 2026 |
| David ScaddenDirector | Option exercise | 2,816 | – | – | Jun 18, 2026 |
| Cynthia SmithDirector | Option exercise | 2,816 | – | – | Jun 18, 2026 |
| Adams Catherine OwenDirector | Option exercise | 1,976 | – | – | Jun 13, 2026 |
| Jeffrey D CapelloDirector | Option exercise | 1,976 | – | – | Jun 13, 2026 |
| James William BurnsChief Legal Officer | Option exercisepre-set plan | 8,500 | – | – | Apr 2, 2026 |
| Sarah GheuensChief Medical Officer | Option exercisepre-set plan | 8,500 | – | – | Apr 2, 2026 |
| Cecilia JonesChief Financial Officer | Option exercisepre-set plan | 8,500 | – | – | Apr 2, 2026 |
| Tsveta MilanovaChief Commercial Officer | Option exercisepre-set plan | 8,500 | – | – | Apr 2, 2026 |
| Krishnan ViswanadhanChief Corp Dev & Strategy | Option exercisepre-set plan | 8,100 | – | – | Apr 2, 2026 |
| Brian GoffChief Executive Officer, Director | Option exercisepre-set plan2 fills | 39,028 | – | – | Apr 2, 2026 |
| Krishnan ViswanadhanChief Corp Dev & Strategy | Option exercisepre-set plan | 8,100 | – | – | Mar 5, 2026 |
| Brian GoffChief Executive Officer, Director | Option exercisepre-set plan3 fills | 39,500 | – | – | Mar 2, 2026 |
| James William BurnsChief Legal Officer | Option exercisepre-set plan4 fills | 17,586 | – | – | Mar 2, 2026 |
| Sarah GheuensChief Medical Officer | Option exercisepre-set plan3 fills | 13,666 | – | – | Mar 2, 2026 |
| Cecilia JonesChief Financial Officer | Option exercisepre-set plan4 fills | 16,969 | – | – | Mar 2, 2026 |
| Tsveta MilanovaChief Commercial Officer | Option exercisepre-set plan2 fills | 9,666 | – | – | Mar 2, 2026 |
| Theodore James Jr. WashburnPrincipal Accounting Officer | Option exercisepre-set plan3 fills | 7,495 | – | – | Mar 2, 2026 |
| Tsveta MilanovaChief Commercial Officer | Option exercisepre-set plan | 8,475 | – | – | Jan 5, 2026 |
| James William BurnsChief Legal Officer | Option exercisepre-set plan | 6,000 | – | – | Dec 30, 2025 |
| Brian GoffChief Executive Officer, Director | Option exercisepre-set plan2 fills | 38,278 | – | – | Dec 30, 2025 |
| Sarah GheuensChief Medical Officer | Option exercisepre-set plan | 6,000 | – | – | Dec 30, 2025 |
| Tsveta MilanovaChief Commercial Officer | Option exercisepre-set plan | 6,000 | – | – | Dec 30, 2025 |
| Cecilia JonesChief Financial Officer | Option exercisepre-set plan | 6,000 | – | – | Dec 30, 2025 |
| David ScaddenDirector | Option exercisepre-set plan | 200 | $18.09 | $3,618 | Nov 12, 2025 |
| Sarah GheuensChief Medical Officer | Option exercisepre-set plan | 2,454 | $25.01 | $61K | Nov 11, 2025 |
| Sarah GheuensChief Medical Officer | Option exercisepre-set plan | 200 | $25.01 | $5,002 | Oct 30, 2025 |
| Sarah GheuensChief Medical Officer | Option exercisepre-set plan | 3,302 | $25.01 | $83K | Oct 27, 2025 |
Trades by members of Congress
1 member reported 5 buys and 0 sales since Jan 29, 2025. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. D | Bought | $1,001–$15K | Aug 20, 2026 | Sep 10, 2026 | Self |
| Gilbert Ray Cisneros, Jr. D | Bought | $1,001–$15K | Mar 3, 2026 | Apr 7, 2026 | Self |
| Gilbert Ray Cisneros, Jr. D | Bought | $1,001–$15K | Dec 11, 2025 | Jan 12, 2026 | Self |
| Gilbert Ray Cisneros, Jr. D | Bought | $1,001–$15K | Apr 17, 2025 | May 6, 2025 | Self |
| Gilbert Ray Cisneros, Jr. D | Bought | $1,001–$15K | Jan 29, 2025 | Feb 11, 2025 | Self |
Latest SEC filings
- Insider plans to sell 144 · Oct 26, 2026
- Insider plans to sell 144 · Oct 22, 2026
- Insider plans to sell 144 · Oct 21, 2026
- Insider plans to sell 144 · Aug 4, 2026
- Quarterly report 10-Q · Jul 30, 2026
- News filing: Quarterly results 8-K · Jul 30, 2026
- Insider plans to sell 144 · Jul 1, 2026
- News filing: Executive or board change, Shareholder vote results 8-K · Jun 18, 2026
- Quarterly report 10-Q · Apr 29, 2026
- News filing: Quarterly results 8-K · Apr 29, 2026
- Shareholder meeting proxy DEF 14A · Apr 24, 2026
- Insider plans to sell 144 · Apr 2, 2026
- Insider plans to sell 144 · Apr 2, 2026
- Insider plans to sell 144 · Apr 2, 2026
- Insider plans to sell 144 · Apr 2, 2026
- Insider plans to sell 144 · Apr 2, 2026
- Insider plans to sell 144 · Apr 2, 2026
- Insider plans to sell 144 · Mar 5, 2026
- Insider plans to sell 144 · Mar 2, 2026
- Insider plans to sell 144 · Mar 2, 2026
- Insider plans to sell 144 · Mar 2, 2026
- Insider plans to sell 144 · Mar 2, 2026
- Insider plans to sell 144 · Mar 2, 2026
- Annual report 10-K · Feb 12, 2026
- News filing: Quarterly results 8-K · Feb 12, 2026
About Agios Pharmaceuticals, Inc.
Business description
- Industry
- Pharmaceutical Preparations
- Sector
- Life Sciences
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Exchange
- Nasdaq
- Filer size
- Large accelerated filer
- Formerly
- AGIOS PHARMACEUTICALS INC
- SEC company number (CIK)
- 1439222
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.